Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Analyzing fundamentals for PBYI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is good and Health is frighteningly weak. For more detailed analysis please see PBYI Fundamentals page.
Watching at PBYI technicals we can see that long-term trend is bullish, the same as bullishmiddle-term trend, but short-term trend is bearish. More technicals details can be found on PBYI Technicals page.
An error has occurred. This application may no longer respond until reloaded.